Licochalcone B alleviates atherosclerosis by inhibiting endothelial inflammation via targeting the KEAP1/NRF2/NF-κB signalling pathway - PubMed
4 hours ago
- #Anti-inflammatory
- #Endothelial cells
- #Atherosclerosis
- Licochalcone B (LCB) reduces atherosclerosis by decreasing plaque area and increasing plaque stability in ApoE-/- mice.
- LCB directly targets KEAP1, promoting its degradation, which activates NRF2 and inhibits NF-κB signaling in endothelial cells.
- This mechanism downregulates adhesion molecules VCAM1 and ICAM1, reducing endothelial inflammation without hepatotoxicity or nephrotoxicity.